Ascentage Operating Margin from 2010 to 2025

AAPG Stock   27.88  1.39  5.25%   
Ascentage Pharma's Operating Profit Margin is increasing over the last several years with stable swings. Operating Profit Margin is predicted to flatten to -0.4.
Check Ascentage Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascentage Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 97.8 M, Interest Expense of 41.4 M or Selling General Administrative of 117.8 M, as well as many indicators such as Price To Sales Ratio of 37.12, Dividend Yield of 0.0 or PTB Ratio of 152. Ascentage financial statements analysis is a perfect complement when working with Ascentage Pharma Valuation or Volatility modules.
  
Build AI portfolio with Ascentage Stock
Check out the analysis of Ascentage Pharma Correlation against competitors.

Currently Active Assets on Macroaxis

When determining whether Ascentage Pharma is a strong investment it is important to analyze Ascentage Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascentage Pharma's future performance. For an informed investment choice regarding Ascentage Stock, refer to the following important reports:
Check out the analysis of Ascentage Pharma Correlation against competitors.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascentage Pharma. If investors know Ascentage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascentage Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.06)
Revenue Per Share
4.78
Quarterly Revenue Growth
(0.72)
Return On Assets
(0.23)
Return On Equity
(1.60)
The market value of Ascentage Pharma is measured differently than its book value, which is the value of Ascentage that is recorded on the company's balance sheet. Investors also form their own opinion of Ascentage Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascentage Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascentage Pharma's market value can be influenced by many factors that don't directly affect Ascentage Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascentage Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascentage Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascentage Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.